Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK138D1 Monotherapy and Combination in Advanced NSCLC
NCT07623356Phase 2Recruiting
- Sponsor
- Akeso, Inc.
- Start
- Jul 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
A Phase 2 trial of AK138D1 in non-small cell lung cancer (NSCLC), sponsored by Akeso, Inc.. Started Jul 2026; status: recruiting.
02
Drugs
AK138D1
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07623356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07623356.